Paris

The trials here

What the 5 trials at this site are about, from their registry records.

Conditions

• Multiple sclerosis3 trials
• COPD2 trials

Phase

• Phase 34 trials

Status

• Completed3 trials
• Active, not recruiting1 trial
• Recruiting1 trial

Lead sponsor

• Sanofi5 trials

Running trials

• Recruiting

  Long-term Real-world Study of Dupilumab in COPD : Patient Characteristics, Safety and Patient-reported Outcomes

  NCT07380711· Sanofi· Source

• Active, not recruiting

  A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.

  NCT06372145· Phase 3· Sanofi· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• COPD1 recruiting

Closed trials

• Completed

  Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (HERCULES)

  NCT04411641· Phase 3· Sanofi· Source

• Completed

  Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate to Severe COPD With Type 2 Inflammation

  NCT04456673· Phase 3· Sanofi· Source

• Completed

  Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (GEMINI 2)

  NCT04410991· Phase 3· Sanofi· Source